271 related articles for article (PubMed ID: 17577054)
21. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
[TBL] [Abstract][Full Text] [Related]
22. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
23. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
25. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
26. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.
Carter JJ; Wipf GC; Benki SF; Christensen ND; Galloway DA
J Virol; 2003 Nov; 77(21):11625-32. PubMed ID: 14557648
[TBL] [Abstract][Full Text] [Related]
27. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
[TBL] [Abstract][Full Text] [Related]
28. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
[TBL] [Abstract][Full Text] [Related]
29. Immunological analyses of human papillomavirus capsids.
Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
[TBL] [Abstract][Full Text] [Related]
30. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
Culp TD; Spatz CM; Reed CA; Christensen ND
Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
[TBL] [Abstract][Full Text] [Related]
31. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
32. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
Rizk RZ; Christensen ND; Michael KM; Müller M; Sehr P; Waterboer T; Pawlita M
J Gen Virol; 2008 Jan; 89(Pt 1):117-129. PubMed ID: 18089735
[TBL] [Abstract][Full Text] [Related]
33. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
34. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
[TBL] [Abstract][Full Text] [Related]
35. Generation and neutralization of pseudovirions of human papillomavirus type 33.
Unckell F; Streeck RE; Sapp M
J Virol; 1997 Apr; 71(4):2934-9. PubMed ID: 9060652
[TBL] [Abstract][Full Text] [Related]
36. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
37. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
38. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
39. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
40. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies.
Bishop B; Dasgupta J; Klein M; Garcea RL; Christensen ND; Zhao R; Chen XS
J Biol Chem; 2007 Oct; 282(43):31803-11. PubMed ID: 17804402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
